Review: A Japanese population-based meta-analysis of vonoprazan versus PPI for Helicobacter pylori eradication therapy: Is superiority an illusion?

Vonoprazan improves the efficacy of Helicobacter pylori eradication therapy with a regimen consisting of clarithromycin and metronidazole in patients allergic to penicillin

(2017) Shoko Ono et al.   HELICOBACTER

The Superiority of Vonoprazan-based First-line Triple Therapy with Clarithromycin: A Prospective Multi-center Cohort Study on Helicobacter pylori Eradication

(2017) Soichiro Sue et al.   INTERNAL MEDICINE

Effects of patient age and choice of antisecretory agent on success of eradication therapy for Helicobacter pylori infection

(2017) Toshihiro Nishizawa et al.   JOURNAL OF CLINICAL BIOCHEMISTRY AND NUTRITION

Screening and treating Helicobacter pylori infection for gastric cancer prevention on the population level

(2017) Yi-Chia Lee et al.   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

Population screening and treatment of Helicobacter pylori infection

(2017) Anthony O'Connor et al.   Nature Reviews Gastroenterology & Hepatology

Comparative study: Vonoprazan and proton pump inhibitors in Helicobacter pylori eradication therapy

(2017) Kouichi Sakurai et al.   WORLD JOURNAL OF GASTROENTEROLOGY

Theeffect of proton pump inhibitors on the gastric mucosal microenvironment

(2017) Yen-Chun Peng et al.   Advances in Clinical and Experimental Medicine

Vonoprazan-Based Regimen Is More Useful than PPI-Based One as a First-LineHelicobacter pyloriEradication: A Randomized Controlled Trial

(2017) Masafumi Maruyama et al.   Canadian Journal of Gastroenterology and Hepatology

The Efficacy and Tolerability of a Triple Therapy Containing a Potassium-Competitive Acid Blocker Compared With a 7-Day PPI-Based Low-Dose Clarithromycin Triple Therapy

(2016) Sho Suzuki et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

A Comparative Study of a New Class of Gastric Acid Suppressant Agent Named Vonoparazan versus Esomeprazole for the Eradication of Helicobacter pylori

(2016) Masahiro Tsujimae et al.   DIGESTION

Helicobacter pylori Eradication with Proton Pump Inhibitors or Potassium-Competitive Acid Blockers: The Effect of Clarithromycin Resistance

(2016) Hiroshi Matsumoto et al.   DIGESTIVE DISEASES AND SCIENCES

The Toronto Consensus for the Treatment of Helicobacter pylori Infection in Adults

(2016) Carlo A. Fallone et al.   GASTROENTEROLOGY

Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy forHelicobacter pylorieradication: a phase III, randomised, double-blind study

(2016) Kazunari Murakami et al.   GUT

Management ofHelicobacter pyloriinfection—the Maastricht V/Florence Consensus Report

(2016) P Malfertheiner et al.   GUT

High antibiotic resistance ofHelicobacter pyloriand its effect on tailored and empiric eradication of the organism in Lower Silesia, Poland

(2016) Stanisław Ferenc et al.   HELICOBACTER

The Changing Profile ofHelicobacter pyloriAntibiotic Resistance in Singapore: A 15-Year Study

(2016) Tiing Leong Ang et al.   HELICOBACTER

Vonoprazanversusconventional proton pump inhibitor-based triple therapy as first-line treatment againstHelicobacter pylori: A multicenter retrospective study in clinical practice

(2016) Satoki Shichijo et al.   Journal of Digestive Diseases

Comparison of vonoprazan and proton pump inhibitors for eradication of Helicobacter pylori

(2016) Satoshi Shinozaki et al.   KAOHSIUNG JOURNAL OF MEDICAL SCIENCES

Analysis of the cost-effectiveness of using vonoprazan–amoxicillin–clarithromycin triple therapy for first-line Helicobacter pylori eradication

(2016) Yusaku Kajihara et al.   SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY

Optimal First-Line Treatment forHelicobacter pyloriInfection: Recent Strategies

(2016) Ju Yup Lee et al.   Gastroenterology Research and Practice

Safety and efficacy of Vonoprazan-based triple therapy against Helicobacter pylori infection: A single-center experience with 1118 patients

(2016) Daisuke Fukuda et al.   Therapeutic Advances in Gastroenterology

Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438 (vonoprazan), a novel potassium-competitive acid blocker, in healthy male subjects

(2015) H. Jenkins et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Acid-inhibitory effects of vonoprazan 20 mg compared with esomeprazole 20 mg or rabeprazole 10 mg in healthy adult male subjects - a randomised open-label cross-over study

(2015) Y. Sakurai et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Review article: the global emergence ofHelicobacter pyloriantibiotic resistance

(2015) I. Thung et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Helicobacter pylori Update: Gastric Cancer, Reliable Therapy, and Possible Benefits

(2015) David Y. Graham   GASTROENTEROLOGY

Primary antibiotic resistance ofHelicobacter pyloristrains isolated from patients with dyspeptic symptoms in Beijing: A prospective serial study

(2015) Yue-Xi Zhang   WORLD JOURNAL OF GASTROENTEROLOGY

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising TAK-438 (Vonoprazan) Doses in Healthy Male Japanese/non-Japanese Subjects

(2015) Yuuichi Sakurai et al.   Clinical and Translational Gastroenterology

Management ofHelicobacter pyloriinfection—the Maastricht IV/ Florence Consensus Report

(2012) Peter Malfertheiner et al.   GUT

The Optimal First-Line Therapy ofHelicobacter pyloriInfection in Year 2012

(2012) Chao-Hung Kuo et al.   Gastroenterology Research and Practice

A Study Comparing the Antisecretory Effect of TAK-438, a Novel Potassium-Competitive Acid Blocker, with Lansoprazole in Animals

(2011) Y. Hori et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS